XML 16 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (USD $)
Dec. 31, 2011
Sep. 30, 2011
CURRENT ASSETS    
Cash and cash equivalents $ 6,773,126 $ 7,507,389
Other receivables 2,027,620 1,608,382
Prepaid expenses and other current assets 301,334 110,818
Marketable securities 71,828 634,585
TOTAL CURRENT ASSETS 9,173,908 9,861,174
PROPERTY AND EQUIPMENT    
Computers, office equipment and furniture 502,508 285,266
Research equipment 4,450,087 3,515
Software 105,916 77,020
Leasehold improvements 2,591,919  
Property, Plant and Equipment, Gross, Total 7,650,430 365,801
Less: Accumulated depreciation and amortization (723,190) (340,364)
PROPERTY AND EQUIPMENT, NET 6,927,240 25,437
OTHER ASSETS    
Rent deposit 6,264  
Patents and other intangible assets 2,749,593 1,731,211
Note Receivable, net 2,314,994 2,272,868
Derivative asset 160,125 161,125
Investment in Nanotope Inc., equity basis 1,543,220 1,649,748
Investment in Leonardo Biosystems Inc., at cost 187,000 187,000
TOTAL OTHER ASSETS 6,961,196 6,001,952
TOTAL ASSETS 23,062,344 15,888,563
CURRENT LIABILITIES    
Accounts payable 714,057 576,809
Accrued expenses 2,386,796 864,511
Accrued payroll and benefits 637,691 195,649
Deferred revenue 101,042  
Derivative liabilities 1,010,883 944,980
Capital lease obligation 209,555  
TOTAL CURRENT LIABILITIES 5,060,024 2,581,949
LONG-TERM LIABILITIES    
Note payable, net of current portion 702,695 606,786
Capital lease obligation, net of current portion 1,444,370  
Other non-current liabilities 106,345 135,660
TOTAL LONG-TERM LIABILITIES 2,253,410 742,446
Commitments and contingencies      
STOCKHOLDERS' EQUITY    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; 1,015 shares issued and outstanding 1  
Common stock, $0.01 par value; 145,000,000 shares authorized; 10,530,524 and 8,642,286 shares issued and outstanding as of December 31, 2011 and September 30, 2011, respectively 105,306 86,423
Additional paid-in capital 136,318,592 127,476,435
Subscription receivable (3,897,500) (900,000)
Accumulated deficit during the development stage (116,357,257) (113,871,752)
Total Arrowhead Research Corporation stockholders' equity 16,169,142 12,791,106
Noncontrolling interest (420,232) (226,938)
TOTAL STOCKHOLDERS' EQUITY 15,748,910 12,564,168
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 23,062,344 $ 15,888,563